A novel standard to evaluate the impact of therapeutic agents on patient safety – The BURDEN OF THERAPY™©∗  by Abdulahad, Ayad K. et al.
lable at ScienceDirect
Contemporary Clinical Trials Communications 4 (2016) 186e191Contents lists avaiContemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctcA novel standard to evaluate the impact of therapeutic agents on
patient safety e The BURDEN OF THERAPY™©*
Ayad K. Abdulahad a, *, 1, Robert J. Snijder b, 1, Moeen K. Panni c, Faysal K. Riaz c,
Andreas J. Karas c
a BOTh Analytics GmbH, Behamstrasse 17, 80687 Munich, Germany
b Astellas Pharma Europe B.V., J.H. Oortweg 62, 2333 BE Leiden, The Netherlands
c Astellas Pharma Europe Ltd, 2000 Hillswood Dr, Chertsey, Surrey KT16 0PS, UKa r t i c l e i n f o
Article history:
Received 20 May 2016
Received in revised form
4 August 2016
Accepted 11 September 2016
Available online 23 September 2016
Keywords:
Burden
Methodology
Quantify
Safety
Severity
Treatment-emergent adverse events©* Intellectual property and Copyrights, BOTh Analy
* Corresponding author.
E-mail addresses: ayad.abdulahad@BOTh-analy
robert.snijder@astellas.com (R.J. Snijder), moeen.pan
faysal.riaz@astellas.com (F.K. Riaz), andreas.karas@ast
1 Contributed equally to this work and joint ﬁrst a
http://dx.doi.org/10.1016/j.conctc.2016.09.003
2451-8654/© 2016 The Authors. Published by Elseviera b s t r a c t
Purpose: Currently, treatment-emergent adverse events (TEAEs) during a clinical study are summarized
over the entire study period.
Objective: Develop and validate a novel methodology, BURDEN OF THERAPY©* (BOTh©*), to quantify
presence and severity of TEAEs on each day of study.
Methods: BOTh utilizes patient-level safety data to derive a quantitative estimate for the burden of TEAEs
that all or individual patients experience on each day of a clinical study. Burden estimate for each day is
based on number and severity of TEAEs. A chart displays the total burden experienced by patients on
each day throughout the study and statistical analyses may be performed with the area under curve.
Methodology was applied to two validated and published clinical studies and statistically analyzed.
Results: In a peripheral neuropathic pain study, the topical group had a greater incidence of TEAEs than
the oral anticonvulsant group when evaluated using current methodology. Utilizing BOTh, TEAEs with
the topical agent were of short duration and occurred for three days after application, whereas TEAEs
with the oral agent increased during dose titration and persisted to study end. In an overactive bladder
study there was a minimal difference in overall TEAEs between groups, but BOTh revealed a higher
burden related to dry mouth in the antimuscarinic versus b3 adrenergic agonist group.
Conclusions: BOTh is a highly sensitive method to evaluate the comparative burden experienced by
patients during treatment, and can facilitate better informed treatment selection. We propose BOTh as
the new standard for analyzing safety during clinical studies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical studies offer a unique opportunity to assess the fre-
quency and severity of treatment-emergent adverse events (TEAEs)
in a controlled and objective setting. The safety and efﬁcacy data of
drugs investigated during clinical studies is one of the most
important pieces of information available to physicians and pa-
tients to determine the choice of treatment. From the perspective of
the patient, survey data suggests that over 75% of outpatientstics GmbH, 2016.
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uthors.
Inc. This is an open access article udesired to be told of every single possible TEAE associated with
their medication [1]. Assessing the tolerability of medications is
important from the perspective of healthcare organizations, as it
may have a negative impact on the level of compliance with
treatment, cost of healthcare, as well as patient quality of life [2,3].
Although it is important to present a detailed analysis of the
tolerability of any medication, detailed safety discussion may be
frequently under-represented in published literature and the
quality and quantity of safety reporting across a range of studies has
been found to be inadequate [4].
A substantial amount of detailed information on the incidence
and presence of TEAEs is recorded during the course of any clinical
study. TEAEs are classiﬁed into various categories to include com-
mon, serious, unexpected, of special interest and drug-related ef-
fects, as well as severity grades such as mild, moderate, severe, life
threatening or mortality [5,6]. Although a wealth of information isnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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safety is on the overall incidence of TEAEs (an absolute number)
during a study. One major drawback to this is that patients who
experience more than one TEAE and their severity on each day of a
study, either contemporaneously or in a consecutive manner, are
not identiﬁed or considered using current methods.
Signiﬁcant improvements can be made in the reporting of safety
information during clinical studies and to further utilize collected
data. However, analyzing TEAEs from the patient perspective and
taking into account all tolerability issues experienced by that pa-
tient on each day of the study, may more accurately represent the
safety burden experienced by patients. In this manuscript, a
method to report the safety burden experienced by patients on
each day of a clinical study is described. Using data from validated
clinical study databases, graphical and quantitative statistical tools
were integrated in this novel method to analyze patient-level safety
data. The utility of modifying this methodology to incorporate
useful efﬁcacy endpoints is also outlined. This method of reporting
safety from a patient perspective is described as “BURDEN OF
THERAPY© (BOTh©).”
2. Methods
2.1. Clinical trial databases
Data from two validated and published non-inferiority clinical
studies were used to investigate the utility of the BURDEN OF
THERAPY methodology: peripheral neuropathic pain database
(ClinicalTrials.gov Identiﬁer: NCT01713426) with a study of topical
vanilloid receptor subtype 1 (TRPV1) agonist and an oral anticon-
vulsant agent; overactive bladder study database (NCT01638000)
with a b3 adrenergic receptor agonist and an antimuscarinic agent
[7,8]. General names for each class of drug treatment are used as the
objective of this manuscript was to primarily investigate the utility
of the BURDEN OF THERAPY methodology.
2.2. Statistical analysis
The mathematical rules applied to derive the BURDEN OF
THERAPY graph and an example calculation are described below.
Assume a subject i has k adverse events in a study, and subject i
was in the study for n days. For this study, h weight elements are
identiﬁed and it is known on which days adverse events (AEs) are
present and onwhich days they are not. The burden on each day for
an individual subject is burdenij:; AEvij ¼ 1 if an AE is present for
subject i on day j; AEvij¼ 0 if an AE is not present for subject i on day
j and Weight_elementuvij ¼ 1 if no additional weight should be
added for AE number v of subject i on day j; Weight elementuvij>1 if
extra weight should be added for AE number v of subject i on day j.
Burdenij is the burden of subject i on day j, based on the k
adverse events that this subject experienced. Weightvij is the
weight of the vth AE that subject i experienced on day j. Weightvij is
the product of the different weight elements (weight_elementuvij),
such as severity, drug discontinuation and seriousness. h in the
equation is the number of weight_element factors taken into ac-
count. So weight_elementuvij is the uth weight element of weight v
for subject i on day j.
Each bar in the BURDEN OF THERAPY graph represents the total
burden of all subjects in the study divided by the subjects at risk,
and can be derived by the sum of the burden of each individual
subject divided by the subjects in the study on day j (nj). The graph
is generated with each bar with length barj, with the order as day
number.
The corrected area under the curve (AUC) for each individual
subject can also be calculated. The corrected AUC represents thetotal burden that an individual subject experienced during the trial
and is the sum of the burden, for all burdens of an individual
subject. The AUC of subject i is, where ti is the total number of study
days of subject i. The AUC can be used in an ANCOVA as a response
variable such that the impact of different covariates and factors on
the AUC can be investigated. Possible factors of interest in a clinical
study may include prior treatment, medication history, age, gender
or body mass index.
2.3. Example BURDEN OF THERAPY analysis
For example, take a ﬁve day study wherein a subject had k ¼ 2
adverse events.
Adverse event 1 (a mild headache) was present on day 2 and day
3 of the study. Adverse event 2 (severe and ongoing dizziness) was
present from day 1 to day 5. On day 3 and day 4 the study treatment
was discontinued because of the dizziness and on day 5 the subject
started using the study treatment again. The weight_elements in
this example are severity (mild ¼ 1, moderate ¼ 2 and severe ¼ 3)
and study drug discontinuation (1 ¼ not discontinued,
2 ¼ temporary discontinued and 3 ¼ permanent discontinued). As
it is known in this study on which days the study drug was dis-
continued, it is decided that the weighting for discontinuation is
only done on the days that the study drug is discontinued else the
weighting ¼ 1.
For day one, only the severe dizziness was present but the drug
was not discontinued yet. The weight factor for day one for dizzi-
ness is ¼ severity * discontinuation ¼ 3  1 ¼ 3.
The weight factor for day 1 for headache is severity *
discontinuation ¼ 1  1 ¼ 1. And the burden on day one for this
subject is ¼ weight headache*presence indicator þ weight dizzi-
ness*presence indicator ¼ 1  0 þ 3  1 ¼ 3.
For day 2 themild headache (weight¼ 1), started and the severe
dizziness was still present but the drugwas still not discontinued so
the burden for day 2 ¼ weight headache*presence
indicator þ weight dizziness*presence
indicator ¼ 1  1 þ 3  1 ¼ 4.
For day 3 the mild headache was still present and the drug was
discontinued because of the dizziness, weight element for discon-
tinuation increased to 2 this gives the burden for day 3 ¼ weight
headache*presence indicator þ weight dizziness*presence
indicator ¼ 1  1 þ 3  2 ¼ 7.
Similarly, the burden for day 4 ¼ weight headache*presence
indicator þ weight dizziness*presence
indicator ¼ 1  0 þ 3  2 ¼ 6; and for day 5 ¼ weight head-
ache*presence indicator þ weight dizziness*presence
indicator ¼ 1  0 þ 3  1 ¼ 3.
The total burden is the sum of the burdens per
day ¼ 3 þ 3þ7 þ 6þ3 ¼ 22. Dividing 22 by the number of days this
subject was in the study gives the corrected AUC ¼ 22/5 ¼ 4.4.
2.4. Data analysis
The application of the BURDEN OF THERAPY methodology in-
volves the use of a clinical study database with individual data
entries for TEAEs per patient per day. The presence of TEAEsmay be
plotted against study day, such that if a patient reported a TEAE
from Days 3e5, this TEAE was considered present on Days 3, 4 and
5. If that patient reported TEAEs of differing severity on a single day,
the worst severity was taken into account in the analysis. Also, if an
end date was not present in the database, or a TEAE was ongoing,
the last study day of the patient was taken as the end day of the
TEAE. The subsequent graph that is produced displays the number
of patients with a TEAE on each study day. The addition of coloring
that corresponds with TEAE severity allows easy discrimination of
Fig. 1. a. BURDEN OF THERAPY assessment of individual patients in a peripheral
neuropathic pain study. b. BURDEN OF THERAPY in a peripheral neuropathic pain
study. TEAE, treatment-emergent adverse event; TRPV1, topical vanilloid receptor
subtype 1.
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In order to visually represent the safety burden experienced by a
patient, varied weighting was applied to TEAE severity in each arm
in a consistent manner. The graph therefore displays the weighted
TEAEs per day. For the purposes of example graphs presented in
this manuscript, TEAEs that were recorded as mild, moderate, and
severe were weighted to represent 1x, 2x, and 3x TEAEs per event
per day, respectively.
By summing up the burden of each day for each patient, with or
without the weighting of events, one can derive an Area Under
Curve (AUC) per patient. This will give a burden estimate for each
patient (see above). Using, for example, an ANCOVAmodel with the
burden estimate as dependent variable and treatment as inde-
pendent variable, one can estimate the treatment effect of the
BOTh. By adding baseline characteristics as covariates, that might
have inﬂuenced the BOTh and the treatment difference of the BOTh,
one can adjust the treatment difference estimates for these
covariates.
In addition to the presentation of TEAEs, the BURDEN OF
THERAPY graph can also be integrated with an efﬁcacy analysis. By
displaying both the efﬁcacy outcome and weighted TEAEs over
time in one graph, it is possible to directly compare the effective-
ness of treatments and their burden on the patient in a single
analysis. Any efﬁcacy endpoint that has been recorded by time may
be used for this type of analysis. Such integrated efﬁcacy and safety
graphs visually describe the tolerability burden and efﬁcacy beneﬁt
of treatment from the patient point of view. An example of an in-
tegrated graph is included in this manuscript.
2.5. BURDEN OF THERAPY graph design
The BURDEN OF THERAPY graph is produced using the SAS®
program. The suggested format for the graph is a mirrored display
bar chart with study day on the y-axis and number of TEAEs on the
x-axis. This design allows convenient comparison of the adverse
event proﬁle per day of each treatment along the horizontal x-axis.
Alternatively, study day can also be presented on the x-axis and
TEAE proﬁles can be compared along the vertical y-axis. The
addition of an efﬁcacy outcome in the graph may be in a line graph
format and in a different color to that used for TEAEs. An alternative
format for the graph is to overlay two treatments on top of each
other. This can be done to compare two treatments that have a
similar safety proﬁle and in conjunction with a comparison of the
mean burden per day. In addition, the difference in TEAEs per day
between treatments can also be plotted.
3. Results
3.1. Peripheral neuropathic pain study
In this study, the total number of patients with TEAEs was 210
(74.5%) in the topical TRPV1 agonist arm and 177 (63.9%) in the oral
anticonvulsant agent arm [7]. A BURDEN OF THERAPY analysis can
be performed on an individual patient level and such an analysis
during this study showed that the presence of TEAEs was different
in the two treatment arms. A greater number of TEAEs were
experienced for a greater number of days with the oral anticon-
vulsant versus the topical TRPV1 agonist (Fig. 1a).
The overall graph of TEAEs shows that there was a noticeable
difference in the presence of events in the two groups as the study
progressed. In the topical TRPV1 agonist group there was an initial
peak followed by a rapid decline in TEAEs per day (Fig. 1b), as they
were primarily transient application site reactions [7]. From Days
1e4, the proportion of patients reporting a TEAE declined (Day 1,
58%; Day 2, 39%; Day 3, 23%; Day 4,17%). Less than 15% of the topicalgroup reported TEAEs for the remainder of the study. In the oral
anticonvulsant group there was a gradual increase and relatively
consistent burden and then minor decrease of burden (Fig. 1b).
Patients reporting TEAEs rose from 11% at Day 1e39% at Day 22,
during the period of dose-titration of the oral agent. For the
remainder of the study up to Day 55, TEAEs were reported by
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the oral anticonvulsant and 23.5 for the topical TRPV1 agonist
(p < 0.0001 for between-group comparison; ANOVA model with
treatment and sex as categorical variables, and sex by treatment as
interaction). The BURDEN OF THERAPY graph highlighted the
contrasting severity of TEAEs in the oral versus topical groups.
There were more weighted moderate and severe TEAEs in the oral
compared with topical group from Days 5e55. TEAE weighting in
both arms allowed this to be more easily visualized as the repre-
sentation of all moderate or severe TEAEs increased in both arms.
The integration of safety and efﬁcacy into the BURDEN OF
THERAPY graph allowed the safety burden to be directly compared
with the median time to treatment response in both arms during
the clinical study. In this study, median time to treatment response
was compared, which was a secondary efﬁcacy endpoint deﬁned as
the ﬁrst of three consecutive days in which the patient reported a
30% reduction in average daily pain score [7]. With the topical
TRPV1 agonist, patients rapidly achieved this median treatment
response (Day 7.5), and this overlapped with the period that tran-
sient application site reactions were observed and then stabilized
to a low background level (reported by <5%). With the oral anti-
convulsant agent, the median treatment response was more
gradual (Day 36.0) and this period coincided with dose-titration
and a gradual increase in reporting of drug-related TEAEs to a
moderate-to-high background level (reported by 20e39%) (Fig. 1b).3.2. Overactive bladder study
In the overactive bladder study, the total number of patients
with TEAEs was 274 (29.3%) in the b3 adrenergic receptor agonist
group and 282 (30.2%) in the antimuscarinic group [8]. Using the
BURDEN OF THERAPY methodology, the presence of weighted
TEAEs per day during the study was observed as similar in bothFig. 2. a. BURDEN OF THERAPY in an overactive bladder study. b. Burden of dry mogroups and differences between the groups were not immediately
noticeable in the chart (Fig. 2a). The overall burden estimate (prior
antimuscarinic use as a covariate) was 19.6 for the antimuscarinic
agent and 15.5 for the adrenergic receptor agonist (p ¼ 0.22 for
between-group comparison). In order to help visualize the differ-
ence between treatment groups, the percentage of patients with a
TEAE per day in each group was overlaid in a single plot and the
difference was also plotted (Fig. 2a). Using this variation of the
BURDEN OF THERAPY methodology, it was possible to identify that
during the study there was a small increase in the proportion of
patients with TEAEs in the antimuscarinic group, which gradually
increased from 0.1% at Day 10 to 5.0% by study end at Day 85.
The antimuscarinic class are known for speciﬁc side effects such
as dry mouth, constipation and headache [9]. In this study, dry
mouth was reported by 29 patients (3.1%) in the adrenergic agonist
group and 54 patients (5.8%) in the antimuscarinic group [8]. An
analysis of patients who reported dry mouth was performed to
investigate whether there was a difference between arms and
approximately 1.5e2.0% of patients reported dry mouth in the
antimuscarinic group from Days 17e85 (Fig. 2b). The burden esti-
mate (prior antimuscarinic use as a covariate) from dry mouth was
5.7 with the antimuscarinic agent and 2.9 for the adrenergic re-
ceptor agonist (p¼ 0.02 for between-group comparison). Therewas
a statistically signiﬁcant difference between treatment groups and
it was more likely that patients reported dry mouth in the anti-
muscarinic group than in the b3 adrenergic receptor agonist group.4. Discussion
The BURDEN OF THERAPY methodology is a novel tool to report
the presence and severity of TEAEs on each day of any clinical study,
providing a visual representation of the comparative burden of any
medication on the patient. It also permits statistical comparisonsuth in an overactive bladder study. TEAE, treatment-emergent adverse event.
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subgroups of interest and the combined presentation of tolerability
and efﬁcacy. The methodology is highly sensitive and permits a
number of more detailed and clinically relevant analyses than
current safety reporting, which is frequently an incomplete sum-
mary over an entire study and does not assess patients who
experience more than one TEAE, or differences in the frequency or
severity of TEAEs on each day during a study. Therefore, the
methodology is a valuable new tool for the quantiﬁcation, pre-
sentation and comparison of TEAEs during a clinical study, as well
as for the assessment of medication safety.
The BURDEN OF THERAPY methodology was applied to two
different validated clinical study databases and several new safety
conclusions were made and quantitatively analyzed in greater
detail. With the peripheral neuropathic pain study, the methodol-
ogy allowed the observation that the burden estimate was signiﬁ-
cantly higher with the oral anticonvulsant compared with the
topical TRPV1 agonist. In particular, patients experienced TEAEs in
the topical group immediately after treatment was applied,
compared to the anticonvulsant group as the agent was titrated and
at its maintenance dose. By combining safety with efﬁcacy into the
BURDEN OF THERAPYgraph, it was possible to track the tolerability
burden and efﬁcacy beneﬁt of treatment during the peripheral
neuropathic pain study. This analysis showed that the topical agent
was associatedwith a rapid treatment response that coincidedwith
transient application site reactions immediately after application.
However, with the anticonvulsant agent, TEAEs gradually increased
during dose titration and persisted until study end, and the efﬁcacy
beneﬁt was delayed until patients received their optimal dose. In a
variation of the methodology with the overactive bladder study, it
was found that there was a signiﬁcantly higher burden associated
with dry mouth with the antimuscarinic agent versus b3 adrenergic
agonist, which was not apparent with traditional reporting
methods. Such a formal statistical analysis shows that by deriving
an AUC with the BURDEN OF THERAPY methodology, the proﬁle of
any TEAE can be compared, and the inﬂuence of any exploratory
variable can also be assessed.
A simple scale of TEAEweighting (1 for mild, 2 for moderate and
3 for severe) was applied in the BURDEN OF THERAPYmethodology
in order tomore accurately reﬂect the clinical impact and burden of
TEAEs on a patient during a study. In clinical practice, TEAEs of
different severities can have a very different level of impact on a
patient. By not applying weighting criteria, a weighting of one is
assumed for all TEAEs and it is also assumed that all TEAEs have an
equal impact or burden on the patient. In theory, additional
weighting could be used in order to reﬂect the seriousness in
addition to the severity of TEAEs. Also, a weighting method could in
the future be standardized for a particular development program,
therapeutic area, or patient population, or particular diseases.
Despite this, the relative advantages and disadvantages of the
weighting scale of TEAEs used in this paper may be a point of
consideration when this methodology is utilized and other means
or criteria of weighting TEAEs may be considered.
The BURDEN OF THERAPY can also be utilized in a personalized
manner as the datasets for individual patients of interest, speciﬁc
patient populations, TEAEs that affect speciﬁc body systems, or
within speciﬁc timelines of a study, can all be analyzed individually
using the methodology. Therefore, the BURDEN OF THERAPY
methodology may help to achieve personalized treatment strate-
gies that may be well tolerated in speciﬁc patient subgroups. In
addition, this methodology can be utilized to assess disease pro-
gression, especially when “treatment failure” outcome measures
are used, in order to provide valuable insight into the TEAEs
experienced by patients, as well as the toxicity related to treat-
ments such as chemotherapy that may continue after patients hadreached such endpoints.
The BURDEN OF THERAPY as described in this manuscript uses
patient level data as collected in clinical studies and with no as-
sumptions regarding pre- or post-study medication burden were
made. However, in the event that one compared a drug that is more
toxic and is associated with more drug-related discontinuations
than its comparator, this method may need adjustment. Possible
solutions may include the simulation of any post-dropout period
based on the pre-dropout period, and the analysis of tolerability
ﬁndings of patients who completed the study.
5. Conclusion
BURDEN OF THERAPY analyses the daily presence and severity
of TEAEs experienced by patients during a clinical study. The
methodology clearly provides a more accurate reﬂection of the
burden of treatment from a patient perspective than current safety
reporting. It is a highly sensitive and versatile tool and may also be
applied in a personalized manner to the datasets of individual pa-
tients of interest, on TEAEs that affect speciﬁc body systems, or
during speciﬁc treatment periods. By integrating efﬁcacy and safety
into the analysis, it is possible to present the risk and beneﬁt of a
therapeutic agent throughout a clinical study. BURDEN OF THER-
APY takes advantage of the wealth of information that is gathered
during a clinical study and does not require additional data
collection. The visual representation of BURDEN OF THERAPY aids
in better informed treatment selection by clinicians and patients.
We therefore propose this novel BURDEN OF THERAPY methodol-
ogy to be considered as a new standard for analyzing safety during
clinical studies.
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